Search - tctmd.com

Displaying 41 - 60 of 83

Sort: Relevancy | Date

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Daily News

Think You Need a Statin? AHA’s Risk Calculator May Disagree

Michael O'Riordan

June 28, 2024

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

News Daily News

Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA

Caitlin E. Cox

June 25, 2024

News Daily News

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Yael L. Maxwell

June 20, 2024

News Daily News

Risk of Death Remains Low a Decade After Primary PCI for STEMI

Caitlin E. Cox

June 18, 2024

News Daily News

Benefits of 12-Month DAPT After CABG Persist to 5 Years: DACAB

Yael L. Maxwell

June 14, 2024

News Daily News

AHA Celebrates a Century by Looking Back, and Forward

Shelley Wood

June 10, 2024

News Daily News

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

L.A. McKeown

June 05, 2024

News Daily News

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

Michael O'Riordan

June 04, 2024

Presentation EuroPCR 2024

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Presenter: Ling Tao

May 15, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

Presentation EuroPCR 2024

Methodological Insight: REC-CAGEFREE II Trial

Presenter: Robert Byrne

May 14, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Daily News

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Michael O'Riordan

May 02, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Advertisement

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Think You Need a Statin? AHA’s Risk Calculator May Disagree

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Risk of Death Remains Low a Decade After Primary PCI for STEMI

Benefits of 12-Month DAPT After CABG Persist to 5 Years: DACAB

AHA Celebrates a Century by Looking Back, and Forward

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Methodological Insight: REC-CAGEFREE II Trial

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Need a Statin for Primary Prevention? There’s an App for That

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content